发明授权
US07638539B2 1, 3, 4-oxadiazol-2-ones as peroxisome-proliferator activated receptor delta modulators and their use in the treatment of neurological and metabolic disease
失效
1,3,4-恶二唑-2-酮作为过氧化物酶体增殖物激活受体δ调节剂及其在治疗神经和代谢疾病中的应用
- 专利标题： 1, 3, 4-oxadiazol-2-ones as peroxisome-proliferator activated receptor delta modulators and their use in the treatment of neurological and metabolic disease
- 专利标题（中）： 1,3,4-恶二唑-2-酮作为过氧化物酶体增殖物激活受体δ调节剂及其在治疗神经和代谢疾病中的应用
-
申请号： US11535764申请日： 2006-09-27
-
公开(公告)号： US07638539B2公开(公告)日： 2009-12-29
- 发明人: Daniel G. McGarry , Jochen Goerlitzer , Stefanie Keil , Karen Chandross , Jean Merrill , Wolfgang Wendler
- 申请人： Daniel G. McGarry , Jochen Goerlitzer , Stefanie Keil , Karen Chandross , Jean Merrill , Wolfgang Wendler
- 申请人地址： US NJ Bridgewater DE Frankfurt Am Main
- 专利权人： Aventis Pharmaceuticals Inc.,Sanofi-Aventis Deutschland GmbH
- 当前专利权人： Aventis Pharmaceuticals Inc.,Sanofi-Aventis Deutschland GmbH
- 当前专利权人地址： US NJ Bridgewater DE Frankfurt Am Main
- 代理商 Jiang Lin; Craig Bell
- 主分类号： A61K31/4245
- IPC分类号： A61K31/4245 ; A61K31/427 ; C07D271/113 ; C07D277/20
摘要：
The present invention is directed to 1,3,4-oxadiazalones, i.e., the compounds of formula I and their pharmaceutically acceptable salts, stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein. The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization such as multiple scleroses.
公开/授权文献
信息查询
